Kornimate/medical-research-clean huggingface dataset:
identification of predictors for early cognitive decline in men

Conditions: Healthy Test Persons; Mild Cognitive Impairment; Alzheimer Disease

Summary: the research program explores how aging influences brain function in test-persons from a danish birth cohort of men born in 1953.

the research program explores how ageing influences brain function in healthy test-persons from a danish birth cohort of men born in 1953 in the metropolitan area of copenhagen. these test-persons are divided into two groups based on performance in cognitive tests at late midlife compared to young adulthood; positive expected performance and negative expected performance and sampled from a birth cohort of 11.532 men. additionally, persons diagnosed with either mci or ad will be included from the memory clinic at herlev hospital. researchers aim to identify factors earlier in life that affects or predict changes in cognitive function, specifically of cognitive decline in order to predict healthy vs unhealthy cognitive ageing, including progression to possible dementia. the objective is to be able to predict cognitive decline in ageing. during the years of data collection, approximately 550 participants will be included and examined. the examinations include: * cognitive test including cambridge neuropsychological test automated battery (cantab); * sleep * life events * depression questionnaire * blood sample analysis including functional analyses of mitochondria and gene analyses such as genome scanning, snp analysis * apoe ε-type * structural and functional changes in the brain measured with magnetic resonance (fmri) * electroencephalography (eeg) recordings of electrical activity and visual attention * pet-scan (amyloid and fdg) the results from these studies will hopefully point to new avenues for intervention in order to change the course of brain ageing

Eligibility criteria:
inclusion criteria: * participants who have participated in the metropolit study and the copenhagen aging and midlife biobank project * participants who have been informed about the project and who have signed the informed consent form exclusion criteria: * persons who have been asked to participate in the past and have rejected * reduced ability to understand project information * reduced ability to complete the examinations * abuse of alcohol, psychedelic drugs or habit-forming drugs * certain neurological disorders * certain neurological, mental or psychiatric diagnoses * certain depressive diseases * former traumatic brain injury * contraindication for mr scanning * pathological mr result * persons that do not like to be informed about a possible pathological result
a study of br alone versus in combination with acalabrutinib in subjects with previously untreated mcl

Conditions: Lymphoma, Mantle Cell

Summary: this study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (br) compared with placebo plus br in subjects with previously untreated mantle cell lymphoma.

to evaluate the efficacy of acalabrutinib in combination with bendamustine and rituximab (br) compared with placebo plus br based on independent review committee (irc) assessment of progression-free survival (pfs) per the lugano classification for non-hodgkin lymphoma (nhl) in subjects with previously untreated mantle cell lymphoma (mcl).

Eligibility criteria:
inclusion criteria: * men and women, ≥ 65 years of age. * pathologically confirmed mcl, with documentation of a chromosome translocation t(11;14)(q13;q32) and/or overexpression of cyclin d1 in association with other relevant markers (eg, cd5, cd19, cd20, pax5) . * mcl requiring treatment and for which no prior systemic anticancer therapies have been received. * eastern cooperative oncology group (ecog) performance status of ≤ 2. * agreement to use highly effective forms of contraception during the study and 6 months after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longest . exclusion criteria: * significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of first dose of study drug, or any class 3 or 4 cardiac disease as defined by the new york heart association functional classification, or corrected qt interval (qtc) \> 480 msec (calculated using friderica's formula: qt/rr0.33) at screening. exception: subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll on study. * malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass. * uncontrolled active systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment), or intravenous anti infective treatment within 2 weeks before first dose of study drug. * concurrent participation in another therapeutic clinical trial.

Keywords: bruton tyrosine kinase inhibitor acalabrutinib mantle cell lymphoma ace-ly-308 treatment naive non-hodgkins lymphoma bendomustine rituximab
pilot study of effect of intravenous lidocaine on propofol requirement in facial plastic surgery

Conditions: Anesthesia, Intravenous; Surgery, Plastic

Summary: the purpose of this randomized pilot study is to evaluate the effect of intravenous lidocaine on propofol requirement during bis (bispectral index) guided mac (monitored anesthesia care) in facial plastic surgery.

several studies reported the usefulness of intravenous lidocaine as a coadjuvant agent during general anesthesia. we thought that there would be an interaction between intravenous lidocaine and hypnotic agent requirement. however, there is no data regarding the effect of systemic lidocaine during mac. we, thus, would like to perform a randomized, double-blinded pilot study to evaluate the effect of intravenous lidocaine on propofol requirement during bis guided mac in facial plastic surgery.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists physical status classification 1 or 2 patients * aged 20-65 years who were undergoing elective facial plastic surgery under monitored anesthesia care exclusion criteria: * unwillingness to participate in the study * adverse reaction to the drugs used in the study * use of medications that interfere in local anesthetic metabolism * history of liver disease or kidney failure * neurological or psychiatric disease * history of drug or alcohol abuse * chronic use of benzodiazepine
grafixpl prime evaluation case study

Conditions: Diabetic Foot Ulcer

Summary: the investigators plan to evaluate healing in a cohort of patients with chronic wounds (n=40) that receive optimal treatment including serial wound debridement and off-loading with total contact casts or a boot and grafixpl prime. in addition, the investigators will collect data on other potential confounding factors that could affect healing such as medications, tobacco, nutrition, comorbidities, diabetes control, infection, perfusion, and activity. wound healing, including wound size and adverse events will be evaluated. the objective of this study is to understand the use of this product to evaluate wound healing in 40 patients.

screening and enrollment: * review and sign the informed consent and hipaa authorization * review the inclusion and exclusion criteria if the subject qualifies for the study, they will participate in the following procedures (weekly visits, +/-4 days): visit 0: * demographics (such as age, gender, race or ethnicity) * medical/surgical and social history, current antibiotics. * laboratory results * vascular - abi * neurological evaluation - monofilament and vpt * vitals - sitting blood pressure and pulse rate, height/weight, and bmi * wound debridement * ekare - wound imaging measurement * application of grafixpl prime * current antibiotics * offloading * adverse events * source documentation visits 1 - 11: * wound debridement * ekare - wound imaging measurement * application of grafixpl prime * current antibiotics * offloading * adverse events * source documentation visit 12/end of study (eos) visit: * wound debridement * ekare - wound imaging measurement * current antibiotics * offloading * adverse events * source documentation (end of study will occur on the date the subject is healed)

Eligibility criteria:
inclusion criteria: * able to provide informed consent * 18-90 years of age * chronic foot ulceration below the ankle - persistent for 30 days or longer * ankle brachial index (abi) \>0.5 (bedside abi is acceptable for screening purposes as the formal imaging abi may not be resulted prior to surgery) exclusion criteria: * unable to provide informed consent * \ 90 years of age * history of poor compliance with follow-up visits * gangrene * untreated osteomyelitis * widespread malignancy * active alcohol or substance abuse such as cocaine, heroin, or methamphetamines * currently pregnant or planning pregnancy during the course of intended participation in the study * is nursing or actively lactating
impact of neuropathic post-zosterian pain on the cognition

Conditions: Neuropathic Post-zosterian Pain; Cognition

Summary: pain is defined as a sensorial and emotional phenomenon and lead consequences on the cognition. these consequences could be increased with usual treatment. so the aim of this study is to explore these cognitive consequences.

pilot prospective study with parallel groups

Eligibility criteria:
inclusion criteria: * patient suffering of npz pain * over 55 years old * healthy volunteers

Keywords: npz pain
pcom2 - the physician communication intervention, version 2.0

Conditions: HPV Infection; Preventive Health Services

Summary: poor quality of primary care providers' vaccine recommendations lead to low adolescent human papillomavirus vaccination rates and hundreds of thousands of adolescents unnecessarily at risk for hpv-associated cancers and diseases. though a previous provider communication intervention, called pcom, was found to be effective for increasing adolescent hpv vaccination in primary care, its dissemination is limited by the need for significant research team involvement to teach providers how to use the intervention's components. to address this, investigators propose to develop and test a virtual version of pcom, use mixed methods to assess contextual factors affecting its use compared to the original pcom intervention, and develop an optimized version of pcom for broad dissemination to increase adolescent hpv vaccination nationally.

the overarching goal is to develop a "virtual" version of the pcom intervention ("pcom-virtual") and compare its efficacy for increasing hpv vaccination among adolescents to that of the original pcom intervention ("pcom-standard"). using dissemination \& implementation (d\&i) science principles to develop and evaluate the pcom-virtual intervention for non-inferiority, investigators anticipate that to have a "shelf ready" intervention and associated "user manual" that can be easily incorporated into practices broadly to improve the practice's adolescent hpv vaccination rates. specific aims are to: (1) develop the "pcom-virtual" intervention using principles of d\&i science; (2) compare the efficacy of "pcom-virtual" versus "pcom-standard" in improving adolescent hpv vaccine utilization; and (3) examine whether practice, patient and provider characteristics are associated with variability in the efficacy of pcom-virtual and pcom-standard.

Eligibility criteria:
inclusion criteria: * parents: have an adolescent between the ages of 9-17 years old and receiving adolescent care at an enrolled clinic * providers: all providers at participating study practices will be eligible to participate. exclusion criteria: * parents: does not have an adolescent between the ages of 9-17 years old and is not receiving adolescent care at an enrolled clinic * providers: providers who are not at participating study practices

Keywords: immunization provider communication hpv prevention
discrete versus rhythmic gait training

Conditions: Stroke; Cerebral Vascular Disorders

Summary: the objective of this study is to compare the effects of novel versus standard locomotor training using a robotic gait orthosis (lt-rgo) after stroke. the hypothesis is that the novel lt-rgo protocol, by establishing a progressive decrease in gait velocity and guidance force, may facilitate greater motor recovery compared to the use of a standard protocol.

standard (rhythmic) robot-assisted locomotor training on a bodyweight-supported treadmill (lt-bwst) used progressively increased speed each week. novel (discrete) robot-assisted lt-bwst used progressive decrease in speed. the novel approach of slowing down the treadmill reduced momentum. if speed had been increased (standard approach), momentum would have increased (momentum = mass \* velocity); and the resulting, passive propulsion of momentum would have diminished the role of cortical skills needed to plan, initiate, and overtly control gait. in sum, the novel protocol used a slower-than-standard treadmill speed in order to provide a window of time sufficient for the corticomotor system to process information, learn, and adjust its response to internal and external feedback (eg, proprioceptive input; therapist input) during robot-assisted lt-bwst.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of stroke and image with hemiparesis left or right; * no more that one ischemic or hemorrhagic stroke episode; * 06 months post-stroke; * verified clinical stability on medical evaluation; * spasticity level i or ii in the ashworth scale; * score 1-2 in the functional ambulation scale (fac); * signed informed consent. exclusion criteria: * dependence to perform activities of daily living before the stroke; * lack of clinical indications for exercises (such as cardiopulmonary instability and uncontrolled diabetes); * severe cognitive impairment; * serious psychiatric change that needs psychiatric care; * severe osteoporosis; * severe spasticity of the lower limbs, deformities or fixed contractures that prevent the achievement of movements; * lack of resistance or disabling fatigue; * body weight greater than 150 kg; * unstable angina or other untreated heart disease; * chronic obstructive pulmonary disease; * unconsolidated fractures, pressure sores; * other neurological diseases.

Keywords: robotics locomotion gait walking rehabilitation
perineural injection and supraspinatus tendenopathy

Conditions: Supraspinatus Tendinopathy

Summary: atotal of 150 consecutive patients with chronic supraspinatous tendinopathy were invited to participate in the study .patients were recruited from the out patient clinic of rheumatology and rehabilitation department,mansoura university hospital a. perineural injection therapy group (subcutaneous prolotherapy) this group included 30 patients aged from 18 to 60 years deep prolotherapy injection group the injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine. the pathological area of the supraspinatous tendon was identified and graded using ultrasound pathology rating scale guided by ultrasonography (simens acuson p300 machine) proper preparation with antiseptic solution of skin overlying the point of injection .

baseline evaluation all patients were subjected to the following: 1. thorough history taking 1. personal history: collected data include: age, sex, marital status, handedness, special habits and the current occupation. 2. complaint in the patient's own words. 3. present history he current symptoms, mode of onset, duration, , factors that may aggravate or relieve pain characters of pain (dull aching,sharp pain ,burning sensation ,parasthesia). distribution of pain . review of systems: symptoms related to rheumatic conditions in particular conditions with predilection for shoulder joint affection. symptoms suggestive of medical disorders e.g. diabetes mellitus or thyroid dysfunction. 4. past history previous significant trauma(direct or occupational) orsugery to shoulder. previous steroid injection to the shoulder. previous injection of any type of regenerative medicine (as prp) 2. thorough general examination 1. general condition. 2. vital signs (pulse, blood pressure, respiratory rate, body temperature) 3. examination of systems (chest,cardiovascular,abdominal,neurological) to identify medical condition that may cause shoulder pain. 3-muscloskeletal examination 1. general muscloskeletal examination examination of all joints for : i.deformity,visible swelling or muscle atrophy ii.palpation for tenderness,warmth,palpable swelling either bony enlargement or synovial effusion. iii.abnormalities in range of motion. iv.diffuse muscloskeletal pain. v.abnormalities of gait.

Eligibility criteria:
inclusion criteria: patients with supraspinatous tendinopathy exclusion criteria: -shoulder joint instability omplete rotator cuff tear adhesive capsulitis septic arthritis malignancy coagulopathy connective tissue diseases spondyloarthropathies previous corticosteroid injection in the last six months. previous other forms of regenerative injection therapy (e.g prp injection therapy) in the last six mo
comparing the protective effects of two cardioplegic solutions, on cardiac metabolism, as assessed using microdialysis

Conditions: Coronary Artery Stenosis

Summary: an estimated 8% to 15% of patients hospitalized for a coronary pathology undergo coronary revascularization surgery with extracorporeal circulation (ecc). (1) like most major cardiac surgical interventions, it is performed with the heart stopped; this leads to more or less severe myocardial ischemia. the heart is stopped (and therefore deprived of oxygen) for a duration that varies depending on the number of bypasses required, and on the local difficulties encountered. on average, myocardial ischemia lasts between 20 and 80 minutes. heart protection during coronary revascularization surgery remains a crucial factor in limiting the heart's aerobic function during aortic clamping, and in minimizing the resulting post-operatory ventricular dysfunction. its quality is a determining factor of the post-operatory issue. high-performance heart protection solutions such as custodiol have been used by heart surgeons for a few years. they are used as an alternative choice to other cardioplegic solutions, the efficacy of which has already been proven (st thomas). these two myocardial protection solutions have never been evaluated in an in vivo, randomized, comparative trial.

myocardial microdialysis is the state-of-the-art technique for evaluating the protective effects of cardioplegic solutions; it enables physicians to monitor oxidation-reduction muscle metabolism during an ongoing operation.

Eligibility criteria:
inclusion criteria: * patient was referred to the cardiovascular surgery unit for surgical coronary revascularization * patient has anterior interventricular stenosis * patient signed the informed consent form * patient is covered by health insurance exclusion criteria: * patients with beating heart surgery indication (no extracorporeal circulation required) * emergency surgery and patients who suffered myocardial infarction less than a week before surgery * iterative surgery

Keywords: coronary artery bypass coronary artery surgery coronary artery bypass graft coronary revascularization cardiac microdialysis custodiol st thomas cardioplegic solutions
ho-1 and muscle mitochondrial dysfunction in sepsis

Conditions: Sepsis; Atrophy

Summary: the current project was designed to examine dynamic changes in muscle wasting during sepsis. researchers will focus the mitochondrial dysfunction of muscle cells and investigate the role of ho-1 in it. researchers interested in identifying factors involved in the pathology of muscle wasting during sepsis.

rapid muscle atrophy or muscle wasting occured to septic patients.sepsis induced muscle wasting has become a severe, frequent, and persistent complication among critically ill patients. multiple factors including ubiquitin-proteasome system, proinflammatory cytokines and oxidative stress contribute muscle proteolysis. it is known that heme oxygenase-1 (ho-1) possesses a variety of functions like anti-inflammatory, antioxidative and anti-apoptosis effects. in order to investigate the mechanisms under the condition, researchers are going to examine the role of ho-1 in muscle atrophy during sepsis.

Eligibility criteria:
inclusion criteria: * sepsis, severe sepsis, septic shock * clinical reason for fixation surgery of femoral fractures exclusion criteria: * no informed consent * medical history of myopathy * unintended weight loss before surgery or icu admission * chronic use of corticosteroids
patient preferences and experiences of waiting for heart surgery

Conditions: Cardiac Disease

Summary: waiting for heart surgery could be difficult and anxiety-provoking for some patients. research suggests that some specific factors (e.g., individual coping strategies, communication with the clinical team, having a more active role in care decision-making) could reduce the stress associated with waiting. however, most of this research has looked at patients waiting for other types of surgery (e.g., cancer surgery). therefore, more research focusing on patients waiting for heart surgery is needed. this project aims to investigate patients' experiences, perceptions and preferences about waiting for elective (non-emergency) heart surgery across four london-based national health service (nhs) hospitals that belong to king's health partners (khp): royal brompton, harefield, st thomas', and king's college hospitals. the project is led by the research team at king's improvement science, (king's college london), in collaboration with clinicians and patients with lived experience of waiting for heart surgery. this project will look at: * how patients feel their heart condition affects their day-to-day life; * how patients experience being on a waiting list; * what factors patients consider as most important for their upcoming surgery (e.g. to have their surgery as soon as possible, at their nearest hospital, or carried out by a specific surgeon); * patients' opinions about how the heart surgery waiting list process could be improved. adult patients (\>18 years old) waiting for elective heart surgery at the four hospitals listed above will be invited, via a text message and a letter, to complete an online survey (i.e. a list of questions). completing reading study information and completing the survey will likely take approximately 30 minutes. the survey will be open for 8 weeks in total. findings from this project, together with other work looking at clinical processes and outcomes across heart surgery services at the four khp hospitals, will inform a wider quality improvement project.


Eligibility criteria:
inclusion criteria: * being on a waiting list for elective cardiac surgery under any of the following surgical prioritisation categories p2, p3, and p4; * being at least 18 years old; * being on a waiting list for cardiac surgery across any of the four khp participating sites: rbh, hh, sth, and kch. exclusion criteria: * being on a waiting list for cardiac surgery at sites other than royal brompton hospital, harefield hospital, st thomas hospital, and king's college hospital; * not having any recorded contact details in the form of mobile phone and home address